Hypoxia and glucose metabolism in malignant tumors: evaluation by [18F]fluoromisonidazole and [18F]fluorodeoxyglucose positron emission tomography imaging.
about
Characterization and performance of a near-infrared 2-deoxyglucose optical imaging agent for mouse cancer modelsNanogels as imaging agents for modalities spanning the electromagnetic spectrumAquaporins and Brain TumorsValidation of functional imaging as a biomarker for radiation treatment responseImaging tumour hypoxia with positron emission tomographyAdvances in molecular imaging for breast cancer detection and characterizationThe clinical importance of assessing tumor hypoxia: relationship of tumor hypoxia to prognosis and therapeutic opportunitiesPositron emission tomography to assess hypoxia and perfusion in lung cancerMechanisms underlying 18F-fluorodeoxyglucose accumulation in colorectal cancerEnergy metabolism in tumor cellsDual-stimuli responsive and reversibly activatable theranostic nanoprobe for precision tumor-targeting and fluorescence-guided photothermal therapy.Radiation treatment monitoring using multimodal functional imaging: PET/CT ((18)F-Fluoromisonidazole & (18)F-Fluorocholine) and DCE-US.Molecular imaging: 18F-FDG PET and a whole lot more.Intratumor mapping of intracellular water lifetime: metabolic images of breast cancer?Mapping human brain capillary water lifetime: high-resolution metabolic neuroimaging.Key Characteristics of Carcinogens as a Basis for Organizing Data on Mechanisms of Carcinogenesis.Analysis of pairwise correlations in multi-parametric PET/MR data for biological tumor characterization and treatment individualization strategies.Co-localisation of hypoxia and perfusion markers with parameters of glucose metabolism in human squamous cell carcinoma (hSCC) xenografts.Apparent diffusion coefficient of glial neoplasms: correlation with fluorodeoxyglucose-positron-emission tomography and gadolinium-enhanced MR imaging.Pharmacokinetic analysis of hypoxia (18)F-fluoromisonidazole dynamic PET in head and neck cancer.Molecular mechanisms of hypoxia in cancer.Fast growth associated with aberrant vasculature and hypoxia in fibroblast growth factor 8b (FGF8b) over-expressing PC-3 prostate tumour xenografts.Molecular imaging of metastatic potential.Noninvasive assessment of tumor microenvironment using dynamic contrast-enhanced magnetic resonance imaging and 18F-fluoromisonidazole positron emission tomography imaging in neck nodal metastases.Effectiveness of combined modality radiotherapy of orthotopic human squamous cell carcinomas in Nu/Nu mice using cetuximab, tirapazamine and MnSOD-plasmid liposome gene therapy.Opportunities for PET to deliver clinical benefit in cancer: breast cancer as a paradigmAnti-Angiogenic/Vascular Effects of the mTOR Inhibitor Everolimus Are Not Detectable by FDG/FLT-PETQuantifying metabolic heterogeneity in head and neck tumors in real time: 2-DG uptake is highest in hypoxic tumor regions.Endoscopic imaging: How far are we from real-time histology?The synthesis of 18F-FDS and its potential application in molecular imaging.Complementary but distinct roles for MRI and 18F-fluoromisonidazole PET in the assessment of human glioblastomas.Specific biomarkers of receptors, pathways of inhibition and targeted therapies: clinical applications.Radiopharmaceuticals in preclinical and clinical development for monitoring of therapy with PETRegulation of the Warburg effect in early-passage breast cancer cells.F-18 fluoromisonidazole for imaging tumor hypoxia: imaging the microenvironment for personalized cancer therapyGlucose deprivation increases nuclear DNA repair protein Ku and resistance to radiation induced oxidative stress in human cancer cellsCombined use of (18)F-FDG and (18)F-FMISO in unresectable non-small cell lung cancer patients planned for radiotherapy: a dynamic PET/CT study.RETRACTED: PET imaging of tumour hypoxia.Imaging oxygenation of human tumours.Hypoxia-inducible factor 1α (HIF-1α) and reactive oxygen species (ROS) mediates radiation-induced invasiveness through the SDF-1α/CXCR4 pathway in non-small cell lung carcinoma cells.
P2860
Q24657493-2996A836-9952-4944-8088-101A11597848Q26741393-98109840-C456-4C98-86A4-B01AEEF64C08Q26745578-B427BF0C-627B-4629-910B-5B63E45C275DQ26823165-4DC98401-1881-4FF0-931A-B8FF03C0361EQ26851422-092482C8-999E-4B92-AE05-28B88851721FQ27000462-C20745CC-C611-4F7F-9B51-E0BF7DF0F124Q27025579-B098BF80-21FE-419D-B682-250AA156E416Q27026940-026080B8-2C0C-4B0E-82F4-DDFD505224DBQ28067736-9891A5E6-1C79-4D96-B51D-3CF90CE593F2Q28288377-03A11429-A6BC-4D36-8DB1-26FBAC84E82FQ30354734-AE03F613-E2E6-4F13-802E-3677BB5D7B1AQ30395717-DE2A5F9F-5AF6-4C6D-AF3D-0A98B7717283Q30482989-AA119C08-CAB7-4D47-AFB8-E774DB7893D5Q30814598-BF2FE41D-2123-4368-A190-7F94BD8ED180Q30939942-B9FE8582-6A9D-4ECA-A8D8-8E41DEF782A1Q31027665-A5EAE47A-355D-47CA-93C2-B2205BA7EABEQ31044830-431C1E7D-BA48-4716-9018-E20114CE1078Q33515391-D95B99DC-5A79-4059-A05A-BE0D8A4ECE3CQ33530806-B9CCD05C-13A4-4C8E-8067-2BEE7A8FA895Q33688715-F946BEBF-9352-4525-AD50-8A465873C57AQ33705108-FE7517B8-2E67-4FD5-9623-C0DCFEAD3724Q33733638-150AB10A-82A4-497D-90FF-D493F9EDE2C4Q33917943-F140E8C4-4118-4946-8FEC-7A651B532E6FQ33925417-E392C457-0FC5-4AFF-A09F-A331FAB5EC69Q33972586-FF333A62-DC26-44F2-A3AC-8B7A8385D630Q33994282-EAD7B00F-1523-4213-AAE4-8A1DEEF5A596Q34041370-106BF15C-C562-4C8E-A9A7-E11A39B6E384Q34050564-3E1B9A2D-D806-463E-89D2-DD6237D6BBD6Q34052244-5591C44F-DE86-44AC-8C5A-64D5CDF26260Q34083386-6A41ACF1-CBA3-43ED-8BC3-D36BC2AEE74FQ34133542-E1F48647-34AC-4DB4-B571-E02695BA7C51Q34203953-14203970-B090-4176-954B-7A50AFA69FE0Q34235986-77AA5F5F-BC2C-4799-895A-14D39A49840DQ34594985-3F3EBE2C-5820-47E8-8558-F8BDF7516C58Q35116993-8C98A25A-24A0-4904-A2DE-A177A3107B7FQ35132901-E151822E-3B68-4FF0-A318-8C01417D3BC0Q35402102-2702E60A-6D3B-4647-881C-26314BFA0939Q35650691-44EC2A1D-23E8-49C1-8A32-EEA1B135D8DEQ35676947-ED09B8DB-B631-4483-A31E-69A5704F8E3DQ35793659-B2991CD0-57D4-422A-83D9-E27D846BB791
P2860
Hypoxia and glucose metabolism in malignant tumors: evaluation by [18F]fluoromisonidazole and [18F]fluorodeoxyglucose positron emission tomography imaging.
description
2004 nî lūn-bûn
@nan
2004 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Hypoxia and glucose metabolism ...... n emission tomography imaging.
@ast
Hypoxia and glucose metabolism ...... n emission tomography imaging.
@en
Hypoxia and glucose metabolism ...... n emission tomography imaging.
@nl
type
label
Hypoxia and glucose metabolism ...... n emission tomography imaging.
@ast
Hypoxia and glucose metabolism ...... n emission tomography imaging.
@en
Hypoxia and glucose metabolism ...... n emission tomography imaging.
@nl
prefLabel
Hypoxia and glucose metabolism ...... n emission tomography imaging.
@ast
Hypoxia and glucose metabolism ...... n emission tomography imaging.
@en
Hypoxia and glucose metabolism ...... n emission tomography imaging.
@nl
P2093
P1476
Hypoxia and glucose metabolism ...... n emission tomography imaging.
@en
P2093
Alexander M Spence
D Greg Farwell
David A Mankoff
David L Schwartz
Ernest U Conrad
Finbarr O'Sullivan
Joseph G Rajendran
Kenneth A Krohn
Lanell M Peterson
P304
P356
10.1158/1078-0432.CCR-0688-3
P407
P577
2004-04-01T00:00:00Z